NCT02491242View on ClinicalTrials.gov

Dolutegravir-based Dual Therapies in HIV-infected Patients With Virological Suppression

CompletedOBSERVATIONAL
Enrollment

155

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

March 31, 2018

Study Completion Date

June 30, 2018

Conditions
HIV Infection
Interventions
OTHER

Dolutegravir in a dual therapy regimen

None. Patients initiating Dolutegravir-based dual therapy because of nucleoside analogues toxicity or intolerance will be followed up during a year

Trial Locations (1)

28034

Ramon y Cajal Hospital, Madrid

All Listed Sponsors
lead

Asociacion para el Estudio de las Enfermedades Infecciosas

NETWORK

NCT02491242 - Dolutegravir-based Dual Therapies in HIV-infected Patients With Virological Suppression | Biotech Hunter | Biotech Hunter